Results 161 to 170 of about 9,220,792 (417)

Evidence of blood–brain barrier dysfunction and CSF immunoglobulin synthesis in Down Syndrome Regression Disorder

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives This study sought to evaluate proteomic, metabolomic, and immune signatures in the cerebrospinal fluid of individuals with Down Syndrome Regression Disorder (DSRD). Methods A prospective case–control study comparing proteomic, metabolomic, and immune profiles in individuals with DSRD was performed.
Jonathan D. Santoro, Neetha Paul Eduthan, Mellad M. Khoshnood, Saba Jafarpour, Natalie K. Boyd, Benjamin N. Vogel, Lina Nguyen, Lilia Kazerooni, Eleanor Britton, Hannah R. Lyford, Matthew D. Galbraith, Angela L. Rachubinski, Joaquin M. Espinosa   +12 more
wiley   +1 more source

Integration of Immunology in a Systems-Based Osteopathic Medical Curriculum

International Medical Education
Immunology is an important component of the medical curriculum. It provides a foundation for understanding the cellular and molecular processes by which the body protects itself from external substances and the immunological responses that contribute to ...
Zian Shabbir, Layla Mazdeyasnan, Naila Iqbal, Samuel Kadavakollu, Mahboob Qureshi, Reena Lamichhane-Khadka   +5 more
doaj   +1 more source

'Clinical immunology' and the'practise of allergy' [PDF]

, 1971
J. Pepys
openalex   +1 more source

The Immunology of Psoriasis—Current Concepts in Pathogenesis

Clinical reviews in allergy and immunology
Psoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the ...
Izabela Siemińska, Monika Pieniawska, Tomasz M Grzywa   +2 more
semanticscholar   +1 more source

If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain–Barré syndrome

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Objectives Intravenous immunoglobulin (IVIg) is an effective treatment for Guillain–Barré syndrome (GBS), but recovery varies between patients. This study aims to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of a single and a second IVIg dose (SID) in patients with GBS.
Sander J. van Tilburg, Ruth Huizinga, Krista Kuitwaard, Sebastiaan D.T. Sassen, Christa Walgaard, Pieter A. van Doorn, Bart C. Jacobs, Birgit C.P Koch   +7 more
wiley   +1 more source

Management and Prevention of Anaphylaxis [version 1; referees: 2 approved]

F1000Research, 2015
Anaphylaxis prevalence has increased within the last few years. This may be due to a marked increase in allergic sensitization to foods especially in the pediatric population, as well as to an increase in outdoor recreational habits and the availability ...
Anne-Marie Irani, Elias G. Akl
doaj   +1 more source

Immunology in Clinical Medicine. [PDF]

, 1970

openalex   +1 more source

Clinical impact and safety of brain biopsy in unexplained central nervous system disorders: a real‐world cohort study

Annals of Clinical and Translational Neurology, EarlyView.
Abstract Objective A substantial part of central nervous system (CNS) disorders remains unexplained, despite various new and minimally invasive diagnostic techniques. Within this rapidly developing diagnostic field, the precise role of brain biopsy is unknown.
Robin W. van Steenhoven, Saan Salih, Juna M. de Vries, Ide Smets, Rob M. Verdijk, Mayke Gardeniers, Jeroen Kerstens, Juliette Brenner, Yvette S. Crijnen, Marjolein Geurts, Jacoline E. C. Bromberg, Corine H. GeurtsvanKessel, Peter A. E. Sillevis Smitt, Rutger K. Balvers, Maarten J. Titulaer   +14 more
wiley   +1 more source

Report of the Committee on Clinical Immunology of the International Union of Immunological Societies (IUIS) [PDF]

, 1977
Elly Budiman‐Mak, Ronald Weitzner, Yongsuk Lertratanakul   +2 more
openalex   +1 more source

Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of iluzanebart, a fully human monoclonal antibody TREM2 (triggering receptor expressed on myeloid cells 2) agonist, after single‐ (SAD) and multiple‐ascending‐dose (MAD) administration.
Andreas Meier, Spyros Papapetropoulos, Andrew Marsh, Kelly Neelon, David Stiles, Ryan O'Mara, Evan A. Thackaberry, Marco Colonna, Raj Rajagovindan   +8 more
wiley   +1 more source